Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASGNMSF 93 3-Year ROIIC % is 2.36 as of Dec. 2025, which is 95% below its 10-year median of 48.02. GuruFocus rates GNMSF with a GF Score™ of 93/100 and a GF Value™ of $347.34 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,322 Biotechnology companies, Genmab AS ranks better than 55.22% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Genmab AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2.36%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Genmab AS's 3-Year ROIIC % or its related term are showing as below:
GNMSF's 3-Year ROIIC % is ranked better than 55.22% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs GNMSF: 2.36
Genmab AS (OTCPK:GNMSF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Genmab AS 3-Year ROIIC % Related Terms
Genmab AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Genmab AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNMSF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Genmab AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Genmab AS's 3-Year ROIIC % falls into.
Genmab AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 999.75 (Dec. 2025) - 708.069215 (Dec. 2022) )
/
( 10303 (Dec. 2025) - 874.941 (Dec. 2022) )
=
291.680785
/
9428.059
=
3.09%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Genmab AS (GNMSF) has a 3-Year ROIIC % of 2.36 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genmab AS and its competitors. This is 95% below median its historical median of 48.02. According to the industry distribution chart, Genmab AS ranks #592 out of 1322 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Genmab AS's 3-Year ROIIC % too high?
Genmab AS's current 3-Year ROIIC % of 2.36 is 95% below median its 10-year median of 48.02. Based on the distribution chart, Genmab AS ranks #592 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #592 out of 1322 companies for 3-Year ROIIC %. This puts Genmab AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genmab AS and its competitors. Genmab AS's current 3-Year ROIIC % is 2.36, which is 95% below median its own 10-year median of 48.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $347.34, compared to a current price of $285.85 — trading 17.7% below its estimated fair value. The current 3-Year ROIIC % is 2.36, which is 95% below median its 10-year median of 48.02. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Genmab AS (GNMSF), the current 3-Year ROIIC % is 2.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $285.85 is trading 17.7% below its estimated GF Value™ of $347.34.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
3-Year ROIIC %: 2.36 (95% below median its 10-year median of 48.02)
GF Value™: $347.34 vs. price of $285.85 (17.7% below fair value)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score
Get the complete analysis for GNMSF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 
